IDBiologics was founded in 2017 to discover and develop human monoclonal antibodies for the prevention, treatment, and cure of infectious diseases.

Our innovative fully human monoclonal antibody platform enables rapid discovery and optimization of broad and potent therapeutic molecules.

Using this proprietary platform, IDBiologics has accumulated unparalleled breadth in isolating antibodies for infectious diseases, with lead candidate molecules to diverse targets moving forward in development.


IDBiologics has best-in-class monoclonal antibodies across a wide range of commercial and global public health indications


Please use the form below or contact us at info@idbiologics.com